CTSC and atrial fibrillation: Further larger and multicenter studies are warranted to elucidate the role of PALS as a sole parameter guiding CA selection, while also validating the clinical utility of emerging biomarkers and comprehensive risk stratification models that incorporate the full spectrum of clinical, echocardiographic, and biochemical predictors of AF recurrence (Figure 2).